Research programme: cancer immuno-therapeutics - Avipep

Drug Profile

Research programme: cancer immuno-therapeutics - Avipep

Alternative Names: ADC-AVP04; ADC-AVP06; Avibody™

Latest Information Update: 25 May 2015

Price : $50

At a glance

  • Originator Avipep
  • Class Antibodies; Drug conjugates; Immunoconjugates
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 17 Apr 2015 Early research in Cancer in Australia (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top